Charles River is the lab partner that pharma companies hire to test new drugs on animals before human trials, running safety checks and supplying the rats and mice used in research.
Money comes from three recurring service lines: selling research animals, running drug safety tests, and biologics quality checks. Gross margin sits at 32.24%, but net margin is negative at -5.96%, so it's not currently profitable.
Regulatory approval processes and long-standing client relationships create switching costs, but competitors like Labcorp and Inotiv offer similar services. The moat is eroding as biotech clients cut spending and push for cheaper alternatives.
Hold (sector percentile 58) — value C, growth D, profitability C, momentum A-, revisions A-. Updated daily, sector-relative, identical for every user.
